Guardant Health, Inc. (NASDAQ:GH) Stock Position Boosted by International Assets Investment Management LLC

International Assets Investment Management LLC increased its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 2,193.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,208 shares of the company’s stock after purchasing an additional 9,763 shares during the period. International Assets Investment Management LLC’s holdings in Guardant Health were worth $2,340,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Quarry LP acquired a new stake in Guardant Health during the second quarter valued at approximately $44,000. Manchester Capital Management LLC acquired a new stake in shares of Guardant Health during the 1st quarter valued at $57,000. Canton Hathaway LLC bought a new stake in shares of Guardant Health during the 2nd quarter worth $59,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Guardant Health in the 2nd quarter worth $71,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Guardant Health during the first quarter worth $75,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Price Performance

NASDAQ GH opened at $23.00 on Monday. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70. The stock has a market capitalization of $2.83 billion, a PE ratio of -5.62 and a beta of 1.11. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04. The company has a 50 day moving average price of $23.15 and a two-hundred day moving average price of $25.72.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The business had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.67) EPS. As a group, equities analysts predict that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on GH shares. TD Cowen lifted their price target on Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Citigroup boosted their price target on shares of Guardant Health from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Craig Hallum raised their price objective on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. BTIG Research increased their target price on Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Finally, Piper Sandler lifted their price target on Guardant Health from $30.00 to $34.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.